Financial Data and Key Metrics Changes - The company delivered total revenue of just over $1 billion, down 0.4% year over year, with core revenue declining 0.7% [18][20] - Adjusted EPS was $0.58, up 4% year over year, driven by stable adjusted EBITDA and lower interest expenses [20][21] - Free cash flow for Q2 was $180 million, with trailing twelve-month free cash flow of $939 million, representing a 14% year-over-year increase [21][30] Business Line Data and Key Metrics Changes - Intelligent Operating Solutions segment saw revenue and core revenue growth essentially flat year over year, with adjusted gross profit at $461 million, down slightly from the prior year [22][24] - Advanced Healthcare Solutions segment delivered total revenue of $320 million, down 1.3% year over year, with adjusted gross margins increasing from just under 58% to just over 59% [26][28] Market Data and Key Metrics Changes - North America showed slight positive growth, while Western Europe, China, and Latin America experienced year-over-year declines [19][20] - The company noted that customer demand pressures were influenced by macroeconomic factors, including tariff uncertainty and constrained government spending [7][19] Company Strategy and Development Direction - The company is focused on executing its Fortive Accelerated strategy, which includes innovation acceleration, commercial acceleration, and enhancing recurring customer value [11][12] - The company is initiating guidance for continuing operations, reflecting a full-year outlook consistent with its new approach of providing clear and simplified guidance [8][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macro pressures and emphasized the importance of the projects in the pipeline for government spending [50][51] - The company anticipates that the revenue slip experienced in Q2 will normalize in the coming quarters, with a strong outlook for the second half of the year [22][55] Other Important Information - The company received a $1.15 billion dividend from the Rallyant spinoff, which was used to pay down debt and fund share repurchases [30][31] - The gross tariff impact for Fortive's continuing operations is expected to be approximately $40 million to $55 million in 2025, with annualized impacts of $80 million to $120 million [29] Q&A Session Summary Question: Insights on second half moving pieces between Q3 and Q4 - Management confirmed that Q3 EPS is expected to be in the low to mid-50s range, with a sequential increase in Q4 driven by tax rate drops and tariff countermeasures [42][44] Question: Government spending and healthcare market outlook - Management noted that while government spending pressures exist, essential projects are still in the pipeline, and healthcare spending is expected to recover as reimbursement policies stabilize [50][51] Question: Clarification on organic sales growth expectations - Management indicated that organic sales growth in Q3 is expected to be consistent with the modest decline seen in Q2, with AHS facing high year-over-year comps [60][64] Question: Renewal rates for Gordian or iOS software - Management reported strong renewal rates across all software businesses, with a focus on expanding and cross-selling to enhance net dollar retention [67][68] Question: Rationale behind not providing high-level organic growth guidance - Management emphasized the intention to simplify communications with investors while maintaining focus on a multi-year value creation plan [73][74] Question: Approach to bolt-on acquisitions - Management clarified that there is a heightened level of scrutiny for bolt-on acquisitions, with a focus on ensuring that each deal meets high strategic and financial criteria [78][79]

Financial Data and Key Metrics Changes - The company delivered adjusted EPS of $0.90 for the final quarter as a consolidated entity, with an 8% growth in trailing twelve months adjusted free cash flow [7][8] - For continuing operations, adjusted EPS was $0.58, reflecting a 4% year-over-year increase, and trailing twelve months free cash flow grew 14% to $939 million [19][20] - Total revenue for Q2 was just over $1 billion, down 0.4% year-over-year, with core revenue declining 0.7% [17][18] Business Line Data and Key Metrics Changes - Intelligent Operating Solutions (IOS) segment saw flat revenue and core revenue growth year-over-year, with adjusted gross profit at $461 million, down slightly from the prior year [21][23] - Advanced Healthcare Solutions (AHS) segment reported total revenue of $320 million, down 1.3% year-over-year, with adjusted gross margins increasing from just under 58% to just over 59% [25][26] Market Data and Key Metrics Changes - North America showed slight positive growth, while Western Europe, China, and Latin America experienced year-over-year declines [18][19] - The company noted that customer demand pressures were influenced by macroeconomic factors, including tariff uncertainty and constrained government spending [7][18] Company Strategy and Development Direction - The company is focused on executing its "Fortive Accelerated" strategy, which aims to drive faster profitable growth and strong shareholder value creation [11][15] - The company is activating its bolt-on M&A engine with a disciplined approach to evaluate deals based on relative returns [15][76] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macroeconomic challenges and emphasized the importance of their capital allocation strategy [15][34] - The company anticipates a modest gross margin and EPS headwind in Q3 due to ongoing tariff impacts, but expects to mitigate these by Q4 [27][30] Other Important Information - The company received a $1.15 billion dividend from the Rallyant spinoff, which was used to pay down debt and fund share repurchases [28][29] - The company initiated full-year adjusted EPS guidance for New Fortive at $2.5 to $2.6 per share, reflecting current market dynamics [30][32] Q&A Session Summary Question: What is the expected EPS for Q3 and Q4? - Management indicated that Q3 EPS is expected to be in the low to mid-50s range, with a potential increase in Q4 due to tax rate drops and other factors [41][45] Question: How are the main end markets expected to perform? - Management noted that government spending pressures and healthcare reimbursement uncertainties impacted Q2, but they expect improvements in the second half of the year [46][50] Question: What is the approach to guidance and disclosure moving forward? - The company plans to provide annual adjusted EPS guidance updated quarterly, focusing on clarity and simplification in communications with investors [72][73] Question: How is the company handling bolt-on M&A? - The company is ready to pursue bolt-on acquisitions with a heightened level of financial and strategic scrutiny, ensuring that each deal meets high standards [76][78]